RecruitingNCT07197957

Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury

Clinical Utility of Cystatin C in the Early Detection of Contrast Induced Acute Kidney Injury


Sponsor

BayCare Health System

Enrollment

100 participants

Start Date

Mar 11, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Subjects ages 18 years and above
  • Inpatients with CKD (Figure 1)
  • Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media.
  • Pre and post contrast available
  • All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study.

Exclusion Criteria8

  • Preexisting dialysis
  • Patients under the age of 18 years
  • Pregnancy
  • Incarcerated individuals
  • Patients with impaired cognition and unable to follow consent procedures
  • Recent exposure to CM (within 2 days before/after procedure)
  • Cardiac shock
  • Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(4)

Morton Plant Hospital

Clearwater, Florida, United States

Morton Plant North Bay Hospital

New Port Richey, Florida, United States

Mease Countryside Hospital

Safety Harbor, Florida, United States

St. Anthony's Hospital

St. Petersburg, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07197957


Related Trials